An epidermal growth factor receptor variant III–targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme

類似資料

• IT-34 PILOT STUDY OF COMBINATION OF ANTITUMOR IMMUNOTHERAPY TARGETED AGAINST CYTOMEGALOVIRUS (CMV) PLUS REGULATORY T-CELL INHIBITION IN PATIENTS WITH NEWLY-DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM)
  著者:: Vlahovic, Gordana, 等
  出版事項: (2014)
• Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme
  著者:: Badruddoja, Michael A., 等
  出版事項: (2007)
• Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma
  著者:: Sampson, John H., 等
  出版事項: (2010)
• Sustained radiographic and clinical response in patient with bifrontal recurrent glioblastoma multiforme with intracerebral infusion of the recombinant targeted toxin TP-38: Case study
  著者:: Sampson, John H., 等
  出版事項: (2005)
• Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: Case study
  著者:: Heimberger, Amy B., 等
  出版事項: (2008)